Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026

Definium Therapeutics Inc. (DFTX) — NEW YORK, September 13, 2026--Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a live webcast tomorrow at 8 a.m. EDT to discuss topline results from Panorama, the Company’s second Phase 3 study of DT120 (lysergide) Orally Disintegrating Tablet (ODT) in adults with generalized anxiet

Source: Business Wire — read the full announcement there.

Browse more sector announcements in our press release archive.